Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the In vivo Elimination of Methotrexate and its Main Toxic Metabolite 7-hydroxymethotrexate

被引:54
作者
Vlaming, Maria L. H. [1 ]
Pala, Zeliha [5 ]
van Esch, Anita [1 ]
Wagenaar, Els [1 ]
van Tellingen, Olaf [2 ]
de Waart, Dirk R. [4 ]
Elferink, Ronald P. J. Oude [4 ]
van de Wetering, Koen [3 ]
Schinkel, Alfred H. [1 ]
机构
[1] Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Div Clin Chem, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, AMC Liver Ctr, NL-1105 AZ Amsterdam, Netherlands
[5] Istanbul Univ, Fac Pharm, Istanbul, Turkey
关键词
D O I
10.1158/1078-0432.CCR-08-1609
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: ATP-binding cassette sub-family C member 2 [ABCC2; multidrug resistance associated protein 2 (MRP2)] and ABCC3 (MRP3) mediate the elimination of toxic compounds, such as drugs and carcinogens, and have a large overlap in substrate specificity. We investigated the roles of Abcc2 and Abcc3 in the elimination of the anticancer drug methotrexate (MTX) and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX) in vivo. Experimental Design: Abcc2:Abcc3(-/-) mice were generated, characterized, and used to investigate possibly overlapping or complementary roles of Abcc2 and Abcc3 in the elimination of MTX and 7OH-MTX after i.v. administration of 50 mg/kg MTX. Results: Abcc2;Abcc3(-/-) mice were viable and fertile. In Abcc2(-/-) mice, the plasma area under the curve (AUQ(i.v)) for MTX was 2.0-fold increased compared with wild type, leading to 1.6-fold increased urinary excretion, which was not seen in Abcc2;Abcc3(-/-) mice. Biliary excretion of MTX was 3.7-fold reduced in Abcc2(-/-) but unchanged in Abcc2;Abcc3(-/-) mice. The plasma AUC(i.v.)s of 7OH-MTX were 6.0-fold and 4.3-fold increased in Abcc2(-/-) and Abcc2;Abcc3(-/-) mice, respectively, leading to increased urinary excretion. The biliary excretion of 7OH-MTX was 5.8-fold reduced in Abcc2(-/-) but unchanged in Abcc2;Abcc3(-/-) mice. 7OH-MTX accumulated substantially in the liver of Abcc2(-/-) and especially Abcc2;Abcc3(-/-) mice. Conclusions: Abcc2 is important for (biliary) excretion of MTX and its toxic metabolite 7OH-MTX. When Abcc2 is absent, Abcc3 transports MTX and 7OH-MTX back from the liver into the circulation, leading to increased plasma levels and urinary excretion. Variation in ABCC2 and/or ABCC3 activity may therefore have profound effects on the elimination and severity of toxicity of MTX and 7OH-MTX after MTX treatment of patients.
引用
收藏
页码:8152 / 8160
页数:9
相关论文
共 40 条
[1]  
Bardelmeijer HA, 2000, CLIN CANCER RES, V6, P4416
[2]   Analysis of the in vivo functions of Mrp3 [J].
Belinsky, MG ;
Dawson, PA ;
Shchaveleva, I ;
Bain, LJ ;
Wang, RX ;
Ling, V ;
Chen, ZS ;
Grinberg, A ;
Westphal, H ;
Klein-Szanto, A ;
Lerro, A ;
Kruh, GD .
MOLECULAR PHARMACOLOGY, 2005, 68 (01) :160-168
[3]   MRP2 and 3 in health and disease [J].
Borst, P ;
Zelcer, N ;
van de Wetering, K .
CANCER LETTERS, 2006, 234 (01) :51-61
[4]   Mammalian ABC transporters in health and disease [J].
Borst, P ;
Elferink, RO .
ANNUAL REVIEW OF BIOCHEMISTRY, 2002, 71 :537-592
[5]   Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles:: Potential role for breast cancer resistance protein in clinical drug-drug interactions [J].
Breedveld, P ;
Zelcer, N ;
Pluim, D ;
Sönmezer, Ö ;
Tibben, MM ;
Beijnen, JH ;
Schinkel, AH ;
van Tellingen, O ;
Borst, P ;
Schellens, JHM .
CANCER RESEARCH, 2004, 64 (16) :5804-5811
[6]   The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models [J].
Breedveld, Pauline ;
Pluim, Dick ;
Cipriani, Greta ;
Dahlhaus, Femke ;
van Eijndhoven, Maria A. J. ;
de Wolf, Cornelia J. F. ;
Kuil, Annemieke ;
Beijnen, Jos H. ;
Scheffer, George L. ;
Jansen, Gerrit ;
Borst, Piet ;
Schellens, Jan H. M. .
MOLECULAR PHARMACOLOGY, 2007, 71 (01) :240-249
[7]  
BREMNES RM, 1989, CANCER RES, V49, P2460
[8]  
Chladek J, 1997, PHYSIOL RES, V46, P371
[9]   Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver [J].
Donner, MG ;
Keppler, D .
HEPATOLOGY, 2001, 34 (02) :351-359
[10]  
FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219